论文部分内容阅读
为探讨Ｃ－ｅｒｂＢ－２蛋白在乳腺癌中的表达及其临床意义，采用免疫组化ＬＳＡＢ法对１０６例乳腺癌标本进行了Ｃ－ｅｒｂＢ－２蛋白检测。结果：Ｃ－ｅｒｂＢ－２蛋白表达阳性率为６３．２１％（６７／１０６）；生存时间≤５年及＞１０年者，其Ｃ－ｅｒｂＢ－２蛋白表达阳性率分别为８１．６３％和３４．２９％。由此提示：Ｃ－ｅｒｂＢ－２蛋白过度表达与乳腺癌的临床分期晚、组织学分级高及腋窝淋巴结转移有关。Ｃ－ｅｒｂＢ－２蛋白的过度表达是判断乳腺癌预后的一个重要因素，可将Ｃ－ｅｒｂＢ－２蛋白检测作为乳腺癌的常规检测指标之一。
To investigate the expression and clinical significance of C-erbB-2 protein in breast cancer, C-erbB-2 protein was detected in 106 breast cancer specimens by immunohistochemical LSAB method. Results: The positive rate of C-erbB-2 protein expression was 63.21% (67/106). The positive rate of C-erbB-2 protein expression was 81.63% in patients whose survival time was ≤5 years and >10 years. 34.29%. This suggests that overexpression of C-erbB-2 protein is associated with late clinical stage, high histological grade and axillary lymph node metastasis. The overexpression of C-erbB-2 protein is an important factor to determine the prognosis of breast cancer. C-erbB-2 protein can be used as one of the routine detection indicators of breast cancer.